ESMO 2024 | Evaluating the anti-emetic effects of olanzapine for patients treated with T-DXd
Hitomi Sakai
• 15 Sep 2024
Hitomi Sakai, MD, Showa University, Tokyo, Japan, comments on the management of long-lasting adverse events such as nausea and vomiting in patients treated with trastuzumab deruxtecan (T-DXd). The Phase II ERICA trial (WJOG14320B) demonstrated that the use of olanzapine has shown to improve patient quality of life, even in cases where these side effects are mild to moderate, offering an important option for symptom management in this population. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
